文献速递淋巴瘤

PET引导放疗在晚期弥漫大B细胞淋巴瘤R-CHOP治疗后的长期结果

Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
PubMed 文献 · Blood · 2021-01-01

该研究纳入2005年至2017年接受至少6周期R-CHOP且治疗结束PET评估的723例晚期DLBCL患者,PET阴性者观察,PET阳性者酌情巩固放疗。中位随访4.3年,PET阴性者3年TTP和OS分别为83%和87%,PET阳性者为56%和64%;PET阳性接受放疗者 outcomes 接近PET阴性者。

要点

  • 治疗结束PET阴性者即使初始有大包块且未放疗,预后仍优异。
  • PET引导的选择性巩固放疗可用于晚期DLBCL,避免不必要放疗。
  • PET阳性且接受放疗者3年TTP和OS达76%和80%。

核心结论

  • 晚期DLBCL患者R-CHOP后PET阴性且未放疗者预后优异,PET可可靠指导选择性巩固放疗。

研究设计与样本

  • 回顾性分析2005年1月1日至2017年3月1日诊断的723例晚期DLBCL患者,均接受至少6周期R-CHOP且治疗结束PET评估。
  • PET阴性者观察,PET阳性者酌情接受巩固放疗。
  • 中位随访4.3年。

主要发现

  • 517例(72%)PET阴性,206例(28%)PET阳性。
  • 3年TTP:PET阴性83% vs PET阳性56%;3年OS:87% vs 64%。
  • PET阳性且非进展性疾病接受巩固放疗者(109/206,53%)3年TTP和OS分别为76%和80%。
  • PET阴性且初始有大包块(≥10 cm)者未放疗, outcomes 与无包块者无差别。

关键数值与推荐

  • PET阴性定义为完全代谢缓解。
  • 大包块定义为诊断时≥10 cm。
  • 巩固放疗在PET阳性且可行时给予。

临床怎么用

  • 晚期DLBCL患者R-CHOP后应行PET评估,PET阴性者可安全省略巩固放疗。
  • PET阳性者可考虑巩固放疗,尤其非进展性疾病。
  • 初始大包块不应作为PET阴性者放疗的独立指征。

局限性

  • 回顾性分析。
  • 单中心政策经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Consolidative radiation therapy (RT) for advanced-stage diffuse large B-cell lymphoma (DLBCL) remains controversial, with routine practice continuing to include RT in patients with initial bulky disease or residual masses. Positron emission tomography (PET)-computed tomography is a sensitive modality for detecting the presence of residual disease at the end of treatment (EOT). A PET-guided approach to selectively administering RT has been the policy in British Columbia since 2005. Patients with advanced-stage DLBCL diagnosed from 1 January 2005 to 1 March 2017 and treated with at least 6 cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone plus rituximab), who underwent EOT PET, were included in this analysis. Those with complete metabolic response (PET-negative [PET-NEG]) were observed; those with PET-positive (PET-POS) scans were offered consolidative RT, when feasible. Of the patient records reviewed, 723 were identified, with median follow-up of 4.3 years: 517 (72%) were PET-NEG; 206 (28%) were PET-POS. Time to progression (TTP) and overall survival (OS) at 3 years were 83% vs 56% and 87% vs 64%, in patients with PET-NEG and PET-POS scans, respectively. PET-POS patients with nonprogressing disease treated with consolidative RT (109 and 206; 53%) had outcomes approaching those of PET-NEG patients, with 3-year estimates of 76% and 80% for TTP and OS. PET-NEG patients who had bulky disease (≥10 cm) at diagnosis had outcomes indistinguishable from those without bulk, despite the omission of RT. These data suggest that patients with advanced-stage DLBCL who are PET-NEG at EOT and receive no RT have excellent outcomes. 18F-fluorodeoxyglucose-PET can reliably guide selective administration of consolidative RT, even in patients with initially bulky disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Freeman CL, Savage KJ, Villa DR, et al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021. PMID: 32871586. doi:10.1182/blood.2020005846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。